Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, announces the launch of its new Ovalbumin Epitope Peptide Antibodies for immunological research by enabling precise and efficient analysis of immune responses. These antibodies can be applied in immunology, allergy, and vaccine development research.
Ovalbumin (OVA), a common allergen found in egg white, is a valuable model antigen in immunological research. Its immunostimulatory properties make it an ideal candidate for studying immune responses. Researchers have extensively studied T-cell and B-cell epitopes associated with OVA, particularly in the context of allergic reactions. In particular, OVA epitope peptides have attracted considerable attention in cancer immunotherapy and vaccine development due to their efficacy in stimulating T cell responses.
OVA is widely used as a model allergen to study IgE-mediated hypersensitivity and food allergy. Numerous studies have mapped partial T and B cell epitopes of OVA using mouse models and sera from allergic patients. The analysis of IgE-binding epitopes in mice offers potential strategies for the design of specific immunotherapies. In addition, research on peptide OVA323-339 is providing insights into the role of T helper cells in allergic inflammation and antibody production. Other OVA peptide research holds promise for the development of peptide-based vaccines, the creation of hypoallergenic molecules and the determination of cross-reactivity between food allergens.
OVA’s versatility extends to its use as a standardized model antigen for evaluating immune responses. Researchers can leverage OVA to compare the efficacy of different vaccine formulations in terms of antibody production and T-cell activation. Moreover, OVA is widely used in preclinical models to assess vaccine efficacy against infectious diseases and cancer. OVA-derived epitopes, such as SIINFEKL, have been shown to be effective in stimulating specific T-cell responses against tumors. By employing OVA epitopes as model targets, researchers can delve into the intricacies of T-cell responses against tumors and explore innovative approaches to enhance anti-tumor immunity, including the development of vaccines that induce robust CD8+ T-cell responses.
Creative Diagnostics offers a wide range of antibodies against OVA epitope peptides (aa 61-68, aa 191-202, aa 257-264, aa 323-339, aa 363-374, etc.) to facilitate scientific research. These antibodies target widely reported epitopes or epitopes similar to human patient IgE epitopes. Tailored to a wide range of applications, these products can be conjugated with different labels to meet specific research needs. By employing these cutting-edge antibodies, researchers can accelerate their investigations and make significant advances in the field of immunology.
Creative Diagnostics is committed to providing researchers with powerful tools to advance their understanding of immune and allergic responses. These new Ovalbumin Epitope Peptide Antibodies have been rigorously tested to meet the highest standards of quality and performance. To learn more about Creative Diagnostics’ OVA Epitope Peptide Antibodies and other research tools, please visit https://www.creative-diagnostics.com/ovalbumin-ova-epitope-peptide-antibodies.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.
Media ContactCompany Name: Creative DiagnosticsContact Person: Thomas SchmittEmail: Send EmailState: New YorkCountry: United StatesWebsite: https://www.creative-diagnostics.com/
